ArticleScientific reports2025
The mechanism of Bletilla striata inhibiting glioma proliferation through the PI3K/AKT/mTOR signaling pathway based on network Pharmacology analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to elucidate the potential mechanisms underlying the therapeutic effects of Bletilla striata in glioma. Targets of Bletilla striata and glioma were predicted using TCMSP, SwissTargetPrediction, GeneCards, and other databases. A "drug-ingredient-target" network and protein-protein interaction (PPI) network were constructed, with core targets identified via topological analysis. Functional enrichment (GO/KEGG, DAVID), molecular docking, and experimental validations (MTT, scratch assay, RT-PCR, Western blot) were performed. A total of 11 active ingredients of Bletilla striata, 456 corresponding targets, and 2,830 glioma-related targets were identified. Nine core targets (AKT1, STAT3, mTOR, etc.) were identified. GO analysis indicated that these targets were primarily involved in phosphorylation, protein binding, and the positive regulation of RNA polymerase II transcription. KEGG analysis highlighted key pathways, including pathways in cancer, the PI3K-AKT signaling pathway, and microRNA-related regulatory mechanisms in cancer. Molecular docking analysis demonstrated high binding affinities between active ingredients and core targets, particularly AKT1 and mTOR. Functional assays showed that Blestriarene A, a key active compound in Bletilla striata, significantly suppressed glioma cell proliferation and migration. RT-PCR results indicated that treatment with varying concentrations of Blestriarene A for 48 h downregulated AKT mRNA expression while upregulating mTOR mRNA expression. Western blot analysis further confirmed a reduction in PI3K, AKT, and mTOR phosphorylation following treatment. Network pharmacology and in vitro experiments suggest that Blestriarene A anti-glioma effects by modulating the PI3K/AKT/mTOR signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.